Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature

Vera, Lara; Oddo, Silvia; Iorgi, Natascia Di; Bentivoglio, G; Giusti, Massimo

doi:10.1186/s13256-016-1093-2

Cited by 44 publications

(35 citation statements)

References 18 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the final weeks of gestation, the foetus needs 25 to 30 g of calcium for bone mineralization 5 . In order to meet those fetal needs, intestinal calcium absorption doubles under mediation by calcitriol, prolactin, and placental lactogen 6 . This calcium is actively transported across the placenta resulting in suppression of fetal PTH secretion until after delivery.…”

Section: Maternal-fetal Complicationsmentioning

confidence: 99%

“…The efficacy and safety of medical management for PHPT in pregnancy are unknown. Hydration and calcitonin have emerged as safe treatments but are considered ineffective for long-term serum calcium control 6 . Intravenously or orally administered hydration (with or without forced diuresis) is the first line of treatment 8 .…”

Section: Medical Treatmentmentioning

confidence: 99%

“…For that reason, calcitonin was not administered in this patient. The use of cinacalcet during pregnancy is debated 6 . Cinacalcet is a calcimimetic agent that binds to the calcium-sensing receptor (CaSR), activating CaSR to react to the extracellular calcium concentration and decrease PTH secretion.…”

Section: Medical Treatmentmentioning

confidence: 99%

“…Its use is limited by the lack of data on the fetus and new-born but animal studies did not show embryonal or fetal toxicity 13 . The use of cinacalcet for treatment of PHPT in pregnancy was reported 6,13 . No adverse fetal effects were reported but in one case the benefit of cinacalcet was weak 6 .…”

Section: Medical Treatmentmentioning

confidence: 99%

“…The use of cinacalcet for treatment of PHPT in pregnancy was reported 6,13 . No adverse fetal effects were reported but in one case the benefit of cinacalcet was weak 6 . Bisphosphonates are commonly used in the treatment of osteoporosis, hypercalcemia, and other conditions characterized by excessive bone resorption.…”

Section: Medical Treatmentmentioning

confidence: 99%

See 4 more Smart Citations

Hiperparatireoidismo primário na gravidez tratado com bisfosfonatos

Tavares¹,

Rocha²,

Machado³

et al. 2019

Gal. Clin.

View full text Add to dashboard Cite

Section: Maternal-fetal Complicationsmentioning

confidence: 99%

Section: Medical Treatmentmentioning

confidence: 99%

Section: Medical Treatmentmentioning

confidence: 99%

Section: Medical Treatmentmentioning

confidence: 99%

Section: Medical Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Hiperparatireoidismo primário na gravidez tratado com bisfosfonatos

Tavares¹,

Rocha²,

Machado³

et al. 2019

Gal. Clin.

View full text Add to dashboard Cite

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop

Bilezikian

Khan

Silverberg

et al. 2020

Journal of Bone and Mineral Research

159

View full text Add to dashboard Cite

The last international guidelines on the evaluation and management of primary hyperparathyroidism (PHPT) were published in 2014. Research since that time has led to new insights into epidemiology, pathophysiology, diagnosis, measurements, genetics, outcomes, presentations, new imaging modalities, target and other organ systems, pregnancy, evaluation, and management. Advances in all these areas are demonstrated by the reference list in which the majority of listings were published after the last set of guidelines. It was thus, timely to convene an international group of over 50 experts to review these advances in our knowledge. Four Task Forces considered: 1. Epidemiology, Pathophysiology, and Genetics; 2. Classical and Nonclassical Features; 3. Surgical Aspects; and 4. Management. For Task Force 4 on the Management of PHPT, Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology addressed surgical management of asymptomatic PHPT and non‐surgical medical management of PHPT. The findings of this systematic review that applied GRADE methods to randomized trials are published as part of this series. Task Force 4 also reviewed a much larger body of new knowledge from observations studies that did not specifically fit the criteria of GRADE methodology. The full reports of these 4 Task Forces immediately follow this summary statement. Distilling the essence of all deliberations of all Task Force reports and Methodological reviews, we offer, in this summary statement, evidence‐based recommendations and guidelines for the evaluation and management of PHPT. Different from the conclusions of the last workshop, these deliberations have led to revisions of renal guidelines and more evidence for the other recommendations. The accompanying papers present an in‐depth discussion of topics summarized in this report. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

show abstract

Management of Primary Hyperparathyroidism

Bilezikian

Silverberg

Bandeira

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Since the last international guidelines were published in 2014 on the evaluation and management of primary hyperparathyroidism (PHPT), new information has become available with regard to evaluation, diagnosis, epidemiology, genetics, classical and nonclassical manifestations, surgical and nonsurgical approaches, and natural history. To provide the most current summary of these developments, an international group, consisting of over 50 experts in these various aspects of PHPT, was convened. This paper provides the results of the task force that was assigned to review the information on the management of PHPT. For this task force on the management of PHPT, two questions were the subject of systematic reviews using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology. The full report addressing surgical and nonsurgical management of PHPT, utilizing the GRADE methodology, is published separately in this series. In this report, we summarize the results of that methodological review and expand them to encompass a much larger body of new knowledge that did not specifically fit the criteria of the GRADE methodology. Together, both the systematic and narrative reviews of the literature, summarized in this paper, give the most complete information available to date. A panel of experts then considered the last set of international guidelines in light of the newer data and assessed the need for their revision. This report provides the evidentiary background to the guidelines report. In that report, evidence from all task forces is synthesized into a summary statement and revised guidelines for the evaluation and management of PHPT. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

show abstract

Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature

Cited by 44 publications

References 18 publications

Hiperparatireoidismo primário na gravidez tratado com bisfosfonatos

Hiperparatireoidismo primário na gravidez tratado com bisfosfonatos

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop

Management of Primary Hyperparathyroidism

Contact Info

Product

Resources

About